Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications
Cell Communication and Signaling · 10.09.2024 · 22 (1)
DOI: 10.1186/s12964-024-01792-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Communication and Signaling, online erschienen am 10.09.2024. Verfasst von Xiangyu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Av…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Lipid Metabolism. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research & Development Program of China.
Abstract (Originalsprache)
BACKGROUND: Endometrial cancer is one of the major gynecological cancers, with increasing incidence and mortality in the past decades. Emerging preclinical and clinical data have indicated its close association with obesity and dyslipidemia. Metabolism reprogramming has been considered as the hallmark of cancer, to satisfy the extensive need of nutrients and energy for survival and growth. Particularly, lipid metabolism reprogramming has aroused the researchers' interest in the field of cancer, including tumorigenesis, invasiveness, metastasis, therapeutic resistance and immunity modulation, etc. But the roles of lipid metabolism reprogramming in endometrial cancer have not been fully understood. This review has summarized how lipid metabolism reprogramming induces oncogenesis and progression of endometrial cancer, including the biological functions of aberrant lipid metabolism pathway and altered transcription regulation of lipid metabolism pathway. Besides, we proposed novel therapeutic strategies of targeting lipid metabolism pathway and concentrated on its potential of sensitizing immunotherapy and hormonal therapy, to further optimize the existing treatment modalities of patients with advanced/metastatic endometrial cancer. Moreover, we expect that targeting lipid metabolism plus hormone therapy may block the endometrial malignant transformation and enrich the preventative approaches of endometrial cancer. CONCLUSION: Lipid metabolism reprogramming plays an important role in tumor initiation and cancer progression of endometrial cancer. Targeting the core enzymes and transcriptional factors of lipid metabolism pathway alone or in combination with immunotherapy/hormone treatment is expected to decrease the tumor burden and provide promising treatment opportunity for patients with advanced/metastatic endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan, Hubei Province, 430030, China.
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan, Hubei Province, 430030, China. xyma@tjh.tjmu.edu.cn.
ORCID-Profile: Xiangyi Ma
Förderung
- National Key Research & Development Program of China
Zitieren
APA
Wang, X., Li, Y., Hou, X., Li, J., & Ma, X. (2024). Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications. Cell Communication and Signaling, 22(1). https://doi.org/10.1186/s12964-024-01792-7
Vancouver
Wang X, Li Y, Hou X, Li J, Ma X. Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications. Cell Communication and Signaling. 2024;22(1). doi:10.1186/s12964-024-01792-7
BibTeX
@article{Wang2024,
author = {Wang, Xiangyu and Li, Yinuo and Hou, Xin and Li, Jingfang and Ma, Xiangyi},
title = {Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications},
journal = {Cell Communication and Signaling},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12964-024-01792-7}
}
EUVIMED